United States - English - NLM (National Library of Medicine)

akorn - timolol (unii: 817w3c6175) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 2.5 mg in 1 ml - timolol is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol is contraindicated in patients with overt heart failure, cardiogenic shock, sinus bradycardia, second- or third-degree atrioventricular block, bronchial asthma or history of bronchial asthma, or severe chronic obstructive pulmonary disease, or hypersensitivity to any component of this product.

United States - English - NLM (National Library of Medicine)

akorn - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 5 mg in 1 ml - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings ]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings ]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. timolol maleate ophthalmic solution, usp 0.5% (ti-moe-lahl mal-ee-ate) read this instructions for use that comes with timolol maleate ophthalmic solution before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timolol maleate ophthalmic solution: how should i use timolol maleate ophthalmic solution? step 1. wash your

United States - English - NLM (National Library of Medicine)

sandoz inc - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 5 mg in 1 ml - timolol gfs 0.25% and 0.5% are indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol gfs is contraindicated in patients with: • bronchial asthma • history of bronchial asthma • severe chronic obstructive pulmonary disease • sinus bradycardia • second or third degree atrioventricular block • overt cardiac failure • cardiogenic shock • hypersensitivity to any component of this product. teratogenic effects pregnancy category c: teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. doses of 1,000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in

United States - English - NLM (National Library of Medicine)

pacific pharma, inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 2.5 mg in 1 ml - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 6.8 mg in 1 ml - timolol maleate ophthalmic gel forming solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic gel forming solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - travoprost, timolol - glaucoma, open-angle; ocular hypertension - ophthalmologicals - decrease of intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 10 mg - timolol maleate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction. timolol is indicated for the prophylaxis of migraine headache. timolol maleate is contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see warnings); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (see warnings); cardiogenic shock; hypersensitivity to this product.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); travoprost, quantity: 40 microgram/ml - eye drops - excipient ingredients: sodium chloride; hydrochloric acid; water for injections; sodium hydroxide; propylene glycol; mannitol; peg-40 hydrogenated castor oil; polyquaternium-1; boric acid - reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension for whom single agent therapy provides insufficient intraocular pressure reduction.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travoprost ophthalmic solution (ionic buffered solution) 0.004% is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. none. risk summary there are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. in animal reproduction studies, subcutaneous (sc) administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. advise pregnant women of a potential risk to a fetus. because animal reproductive studies are not always predictive of human response, travoprost should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - timolol maleate 6.8 mg/ml (equivalemt to 5.0 mg/ml timolol); travoprost 40 µg/ml - eye drops, solution - 0.004%, 0.5% - active: timolol maleate 6.8 mg/ml (equivalemt to 5.0 mg/ml timolol) travoprost 40 µg/ml excipient: boric acid hydrochloric acid polyoxyethylene hydrogenated castor oil 40 mannitol polidronium chloride propylene glycol purified water sodium chloride sodium hydroxide - duotrav is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension for whom single agent therapy provides insufficient intraocular pressure reduction.